Polyphor AG: Outer-Membrane Protein Targeting Antibiotics - New hope against antibiotic resistance. Polyphor AG: Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope against antibiotic resistance
EQS Group-News: Polyphor AG / Schlagwort(e): Studie
Polyphor AG: Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New
hope against antibiotic resistance
24.04.2017 / 18:15
Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope against
- Important step forward for nosocomial pneumonia treatment -
Vienna, Austria, April 24, 2017 - Polyphor today presented promising data
for their novel class of antibiotics, the Outer Membrane Protein Targeting
Antibiotics (OMPTA). This is the first new class of antibiotic against
Gram-negative pathogens to reach advanced clinical development in over 40
years. Murepavadin (POL7080), the first member of the OMPTA class -
currently in Phase II and soon expected to enter Phase III - is being
developed for the treatment of the most severe Pseudomonas aeruginosa (PA)
infection - nosocomial pneumonia (including hospital-acquired and
ventilator-associated pneumonia) - a disease with a death rate of 20-50%.1
Early initiation of effective antimicrobial treatment for PA pulmonary
infections is critical and a strong predictor of mortality.2 However,
multi-drug resistant (MDR) PA has become a global problem and, as such,
treatment is becoming more challenging with limited options available.
Murepavadin, by means of its novel and unique mechanism of action, is
extremely active and is being developed as first line treatment for MDR
Dr Ignacio Martin-Loeches, St James' Hospital, Trinity College, Dublin
(Ireland) explained, "PA represents a significant threat to the most
vulnerable hospital patients, including intensive care patients, those with
depleted immune systems such as those with cancer, people with severe burns
and premature babies in neonatal units. Treatment options are limited and so
this new class of antibiotics is desperately needed."
Data presented today at the 27th European Congress of Clinical Microbiology
and Infectious Diseases (ECCMID) have shown a high rate of clinical cure
(91%) and low rate of mortality (9%) at day 28 in a small patient group (12
patients), when treated with Murepavadin.3 They also demonstrated that
multiple doses of Murepavadin were considered to be safe and with acceptable
"Antibiotic resistance is one of the most serious health threats of our time
with significant global implications. New treatment options are urgently
needed", highlighted Prof. Antoni Torres, Respiratory Institute Hospital
Clinic, Barcelona (Spain). "Today's announcement that Murepavadin has shown
positive benefits in the trials offers hope for the management of this
challenging patient group."
Dr Glenn Dale, Head of Early Development, Antimicrobials, Polyphor added,
"Murepavadin's single pathogen focus prevents a build-up of resistance
against other pathogens, which is a common problem with antibiotics. Today's
findings show that our proposed dose of Murepavidin could be a promising new
antimicrobial to treat PA.4 This year, we expect Murepavadin to enter Phase
III trials and take another step to bring it to patients. In addition, our
OMPTA platform could bring further new important therapies in the treatment
of Gram-negative pathogens."
Catherine Hof Jo Hewitt
Corporate Communications Director
Polyphor Ltd HAVAS Just::
Tel: +41 61 567 16 00 Tel: +44 208 877 8421
Email: PR@polyphor.com Email: firstname.lastname@example.org
1. mailto:email@example.com 1. mailto:firstname.lastname@example.org
Polyphor is a clinical stage, privately held Swiss specialty pharma company,
focused on the development of macrocycle drugs that address antibiotic
resistance and severe respiratory diseases. The company's lead drug
- Murepavadin (POL7080, in Phase II entering Phase III / Pivotal
registration program), a precision Outer Membrane Protein Targeting
Antibiotic (OMPTA) against Pseudomonas Aeruginosa.
- POL6014 (in Phase Ib), an inhaled inhibitor of neutrophil elastase for the
treatment of cystic fibrosis and other severe lung diseases.
- Balixafortide (POL6326, in Phase Ib), an antagonist of the chemokine
receptor CXCR4 for combination treatment in oncology.
Polyphor has discovered the OMPTA class and is further developing it,
including a broad-spectrum preclinical candidate, to address infections
caused by difficult-to-treat, resistant Gram-negative pathogens - one of the
most pressing emerging medical needs. The OMPTA represent the first new
class of antibiotics against Gram-negative bacteria reaching advanced
clinical stage in the last 40 years.
In addition, Polyphor has an important activity of discovery technology
partnerships to assist pharma companies in research programs addressing
difficult targets through its proprietary macrocycle technology platform.
Polyphor has several industry partnerships with and financing from the
Cystic Fibrosis Foundation Therapeutics, Gilead Sciences, Novartis, Taisho
and the Wellcome Trust.
1. Zhang Y, et al. Mortality attributable to carbapenem-resistant
Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg
Microbes Infect. 2016. Available here:
http://www.nature.com/emi/journal/v5/n3/full/emi201622a.html (accessed 20
2. Micek ST, et al. An international multicenter retrospective study of
Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.
Crit Care. 2015;19:219.
3. Armaganidis A, et al. Pharmacokinetic and efficacy analysis of
Murepavadin (POL7080) co-administered with standard-of-care (SOC) in a Phase
II study in patients with ventilator associated pneumonia (VAP) due to
suspected or documented Pseudomonas aeruginosa infection. Poster 1308,
4. Machacek M, et al. Population pharmacokinetics modeling of Murepavadin
(POL7080) and simulation of target attainment in a population with
ventilator-associated pneumonia due to infection with Pseudomonas aeruginosa.
Poster 1307, ECCMID 2017.
Zusatzmaterial zur Meldung:
Ende der Medienmitteilung